{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282680203352192.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1536/ihj.14-217"}},{"identifier":{"@type":"PMID","@value":"25318555"}},{"identifier":{"@type":"DOI","@value":"10.1536/ihj.14-190"}},{"identifier":{"@type":"PMID","@value":"25318553"}},{"identifier":{"@type":"URI","@value":"https://www.jstage.jst.go.jp/article/ihj/55/6/55_14-190/_pdf"}},{"identifier":{"@type":"URI","@value":"https://www.jstage.jst.go.jp/article/ihj/55/6/55_14-217/_pdf"}},{"identifier":{"@type":"NAID","@value":"130004699233"}},{"identifier":{"@type":"NAID","@value":"130004699232"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2015215306"}}],"resourceType":"エディトリアル(editorial)","dc:title":[{"@language":"en","@value":"Aquaporin-2-Guided Tolvaptan Therapy in Patients With Congestive Heart Failure Accompanied by Chronic Kidney Disease"},{"@value":"Effect of Tolvaptan in Patients With Chronic Kidney Disease Due to Diabetic Nephropathy With Heart Failure"}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"The efficacy of tolvaptan for treating heart failure has already been shown. Adequate data relating to the effect of tolvaptan on the correlation of water balance in renal disease are not available. A retrospective study was conducted on the efficacy and adverse reactions of tolvaptan for treating nephrotic syndrome.<br>The subjects were 26 patients with chronic kidney failure due to diabetic nephropathy with heart failure who were administered tolvaptan and seen between December 2011 and October 2013. The endpoints were urinary output, physical findings, and blood analyses. The expression of aquaporin-2 in the collecting duct, which is related to the action of tolvaptan, was investigated by immunohistochemistry using the kidney tissue obtained for the diagnosis.<br>Responses were seen in 19 of the patients. In the histopathological investigation there was severe glomerulosclerosis in patients with diabetic nephropathy, but the responders were noticeable in that they only had mild tubulointerstitial damage. Non-responders exhibited profound tubulointerstitial damage. The expression of aquaporin-2 was determined in 8 patients, of which 7 were responders who tested positive for aquaporin-2. The remaining case was a non-responder who showed no expression of aquaporin-2.<br>Tolvaptan is considered effective for some cases of nephrotic syndrome. There are no clear parameters for predicting an effect, but the present study showed that aquaporin-2 was expressed in the epithelial cells of the collecting ducts of tolvaptan responders."}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410282680203352192","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000265534887"}],"foaf:name":[{"@language":"en","@value":"Imamura Teruhiko"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13492365"},{"@type":"LISSN","@value":"13492365"},{"@type":"EISSN","@value":"13493299"}],"prism:publicationName":[{"@language":"en","@value":"International Heart Journal"},{"@language":"en","@value":"Int. Heart J."}],"dc:publisher":[{"@language":"en","@value":"International Heart Journal Association"},{"@language":"ja","@value":"一般社団法人 インターナショナル・ハート・ジャーナル刊行会"}],"prism:publicationDate":"2014","prism:volume":"55","prism:number":"6","prism:startingPage":"482","prism:endingPage":"483"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"https://www.jstage.jst.go.jp/article/ihj/55/6/55_14-190/_pdf"},{"@id":"https://www.jstage.jst.go.jp/article/ihj/55/6/55_14-217/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2015215306"}],"availableAt":"2014","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Histopathological%20findings","dc:title":"Histopathological findings"},{"@id":"https://cir.nii.ac.jp/all?q=Aquaporin-2","dc:title":"Aquaporin-2"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360003500472515712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA."}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231252534144","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tolvaptan therapy for massive edema in a patient with nephrotic syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144208742400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283694802609408","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pathologic Classification of Diabetic Nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619345100160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Aquaporin‐2 regulation in health and disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621436295424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct."}]},{"@id":"https://cir.nii.ac.jp/crid/1360567189446332928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095402332288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart Failure<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>"}]},{"@id":"https://cir.nii.ac.jp/crid/1360586669068856448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of the V2-Receptor Antagonist OPC-41061 and the Loop Diuretic Furosemide Alone and in Combination in Rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1360866926273051648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044236347136","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Experience of a Vasopressin Receptor Antagonist, Tolvaptan, Under the Unique Indication in Japanese Heart Failure Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045442044288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Aquaporin Expression in Normal Human Kidney and in Renal Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045765535488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rationale and Design of the Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993486912384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure<SUBTITLE>The EVEREST Outcome Trial</SUBTITLE>"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993517129472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993978902912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Relationship between heart failure treatment and development of worsening renal function among hospitalized patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469597809792","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Urinary excretion of aquaporin-2 water channel protein in human and rat."}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844595124352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"New insights into the dynamic regulation of water and acid-base balance by renal epithelial cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845589523840","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Deficiency of the Calcium-Sensing Receptor in the Kidney Causes Parathyroid Hormone–Independent Hypocalciuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846049707520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study)"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794040046592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cloning and expression of apical membrane water channel of rat kidney collecting tubule"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205108968192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy and Safety of Tolvaptan in Heart Failure Patients With Volume Overload"},{"@value":"LATE BREAKING COHORT STUDIES (JCS 2014) : Efficacy and Safety of Tolvaptan in Heart Failure Patients With Volume Overload : An Interim Result of Post-Marketing Surveillance in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205224685184","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Reverse Remodeling Achieved by Combination Therapy With High-Dose Beta Blocker and Cardiac Resynchronization"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205224725504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Tolvaptan Reduces Long-Term Total Medical Expenses and Length of Stay in Aquaporin-Defined Responders"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205224807168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205224838400","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Assessment of Quality of Life During Long-Term Treatment of Tolvaptan in Refractory Heart Failure"},{"@value":"Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: design and rationale of the AQUA-TLV study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205226309248","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Combination of Urinary Sodium/Creatinine Ratio and Plasma Brain Natriuretic Peptide Level Predicts Successful Tolvaptan Therapy in Patients With Heart Failure and Volume Overload"}]},{"@id":"https://cir.nii.ac.jp/crid/1390008299691821696","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The Efficacy and Renal Protective Effect of Tolvaptan in Chronic Kidney Disease Patients after Open-Heart Surgery"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772082432","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"3．トルバプタンの使用について―腎臓内科の立場から―"},{"@language":"en","@value":"Tips for use of tolvaptan -From a nephrologist to gastroenterologists-"},{"@value":"トルバプタンの使用について : 腎臓内科の立場から"},{"@language":"ja-Kana","@value":"トルバプタン ノ シヨウ ニ ツイテ : ジンゾウ ナイカ ノ タチバ カラ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679851293824","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679852787840","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680078427776","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Novel Criteria of Urine Osmolality Effectively Predict Response to Tolvaptan in Decompensated Heart Failure Patients"},{"@value":"Urine Osmolality-Guided Tolvaptan Therapy in Decompensated Heart Failure"},{"@value":"Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients-association between non-responders and chronic kidney disease"},{"@value":"Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients—Association between non-responders and chronic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680200972544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Preliminary Report of Tolvaptan Treatment in Japanese Patients With Heart Failure"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680201116928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A Case With Recovery of Response to Tolvaptan Associated With Remission of Acute Kidney Injury and Increased Urine Osmolality"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680201664000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Urine Sodium Excretion After Tolvaptan Administration Is Dependent Upon Baseline Serum Sodium Levels"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680202398208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Tolvaptan Can Improve Clinical Course in Responders"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680203246592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282752344058624","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Long-Term Tolvaptan Treatment in Refractory Heart Failure"}]},{"@id":"https://cir.nii.ac.jp/crid/1390573715159506688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"JCS/JSCVS/JATS/JSVS 2021 Guideline on Implantable Left Ventricular Assist Device for Patients With Advanced Heart Failure"}]},{"@id":"https://cir.nii.ac.jp/crid/2050307417120716416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure"}]},{"@id":"https://cir.nii.ac.jp/crid/2050870367074117632","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Decreased expression of aquaporin 2 in the collecting duct of mice lacking the vasopressin V1a receptor"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:1004133517"},{"@type":"JALC","@value":"oai:japanlinkcenter.org:1004133516"},{"@type":"CROSSREF","@value":"10.1536/ihj.14-190"},{"@type":"CROSSREF","@value":"10.1536/ihj.14-217"},{"@type":"PUBMED","@value":"25318555"},{"@type":"PUBMED","@value":"25318553"},{"@type":"CIA","@value":"130004699233"},{"@type":"CIA","@value":"130004699232"},{"@type":"OPENAIRE","@value":"doi_dedup___::fe7a8ad12e39dffe81550c5fd7c9cb2f"},{"@type":"OPENAIRE","@value":"doi_dedup___::709f3d5de5a9d178bb4a3693f3ad9102"},{"@type":"CROSSREF","@value":"10.1253/circrep.cr-19-0064_references_DOI_2w7E5ESFEAfxR94J9a6OLVGaj5S"},{"@type":"CROSSREF","@value":"10.5761/atcs.oa.20-00364_references_DOI_NERusPSkLqAyFPFEonwdHy9sZu6"},{"@type":"CROSSREF","@value":"10.2957/kanzo.58.85_references_DOI_NERusPSkLqAyFPFEonwdHy9sZu6"},{"@type":"CROSSREF","@value":"10.1536/ihj.16-007_references_DOI_2w7E5ESFEAfxR94J9a6OLVGaj5S"},{"@type":"CROSSREF","@value":"10.3390/ijms17010105_references_DOI_NERusPSkLqAyFPFEonwdHy9sZu6"},{"@type":"CROSSREF","@value":"10.3390/ijms17010105_references_DOI_2w7E5ESFEAfxR94J9a6OLVGaj5S"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.56.7539_references_DOI_2w7E5ESFEAfxR94J9a6OLVGaj5S"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.56.7539_references_DOI_NERusPSkLqAyFPFEonwdHy9sZu6"},{"@type":"CROSSREF","@value":"10.1536/ihj.15-330_references_DOI_NERusPSkLqAyFPFEonwdHy9sZu6"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-21-0880_references_DOI_2w7E5ESFEAfxR94J9a6OLVGaj5S"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.55.7133_references_DOI_NERusPSkLqAyFPFEonwdHy9sZu6"},{"@type":"CROSSREF","@value":"10.1536/ihj.15-003_references_DOI_2w7E5ESFEAfxR94J9a6OLVGaj5S"},{"@type":"CROSSREF","@value":"10.1536/ihj.16-023_references_DOI_2w7E5ESFEAfxR94J9a6OLVGaj5S"},{"@type":"CROSSREF","@value":"10.1536/ihj.15-297_references_DOI_2w7E5ESFEAfxR94J9a6OLVGaj5S"}]}